AG957
| 规格 | 价格 | 货期 | 数量 |
|---|---|---|---|
| 5mg | ¥1578.00 | 现货 | |
| 10mg | ¥2927.00 | 现货 |
特色产品
- 用于免疫印迹和质谱分析等后续操作
- 适用于30 KDa-130 KDa大小的蛋白
- 可将信号灵敏度提高100倍
- 同时保持稳定的特异性和分辨率
- 提供更高的转录效率并抑制免疫激活
- 使用5-moUTP和Cy5-utp修饰
产品描述
AG957 is a tyrosine phosphorylation inhibitor that targets transforming Bcr-Abl fusion proteins (p185Bcr-Abl, p210Bcr-Abl), as well as normal c-Abl [1].
The abl proto-oncogene is expressed in all cell types. The protein p140c-abl is localized both to the nucleus and the cytoplasm. The abl transforming proteins p160gag-abl, p210bcr-abl, and p185bcr-abl are exclusively cytoplasmic proteins. The intrinsic protein tyrosine kinase activity of the transforming abl proteins is higher than that of the normal p140c-abl [1].
AG957 is a tyrosine phosphorylation inhibitor. AG957 inhibited human p185Bcr-Abl, p210Bcr-Abl and normal c-Abl with IC50 values of 4.3, 1, and 7.1 μM, respectively. AG957 inhibited mouse normal c-Abl with IC50 value of 6 μM. AG957 also inhibited epidermal growth factor receptor with IC50 value of 0.25 μM. In chronic myelogenous leukemia (CML) K562 cells, AG957 inhibited p210bcr-abl kinase activity and cell growth. AG957 at 20 μM also inhibited DNA synthesis as early as 2 h by 60% [2]. In K562 cells, AG957, a selective Bcr-Abl inhibitor, blocked taxol-induced PKCi activation and sensitized these cells to taxol-induced apoptosis [3].
In mice, AG957, the c-Abl inhibitor, attenuated LPS-induced pulmonary permeability [4].
References:
[1]. Anafi M, Gazit A, Gilon C, et al. Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J Biol Chem. 1992 Mar 5;267(7):4518-23.
[2]. Kaur G, Gazit A, Levitzki A, et al. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs. 1994 Apr;5(2):213-22.
[3]. Jamieson L, Carpenter L, Biden TJ, et al. Protein kinase Ciota activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis. J Biol Chem. 1999 Feb 12;274(7):3927-30.
[4]. Fu P, Usatyuk PV, Lele A, et al. c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. Am J Physiol Lung Cell Mol Physiol. 2015 May 15;308(10):L1025-38.
产品性质
| 物理外观 | A crystalline solid |
| CAS号 | 140674-76-6 |
| 分子式 | C15H15NO4 |
| 分子量 | 273.3 |
| 化学名称 | 4-[[(2,5-dihydroxyphenyl)methyl]amino]-benzoic acid, methyl ester |
| 溶解度 | insoluble in H2O; ≥15.2 mg/mL in EtOH; ≥32.3 mg/mL in DMSO |
| SMILES | COC(c(cc1)ccc1NCc(cc(cc1)O)c1O)=O |
| 存储条件 | -20°C |
| 运输条件 | 蓝冰 |
产品应用 (实验数据来自文献,APExBIO并未验证,仅供参考)
IC50和靶点
| 生物活性描述 | AG957(Tyrphostin AG957;NSC 654705)是一种具有抗 BCR/ABL 酪氨酸激酶活性的酪氨酸激酶抑制剂。AG957 是一种 bcr/abl 激酶抑制剂,对 p210bcr/abl 自激酶活性的 IC50 值为 2.9 μM。 |



沪公网安备 31011002003500